Uses of Romenam

Romenam belongs to the group of antiparasitic, anti-infective, anti-viral, anti-fungal drugs used to treat infections in adults and children caused by bacteria sensitive to meropenem. Below is detailed information about what Romenam is and what to watch out for.

Romenam medicine is prepared in the form of a powder for injection, with the main ingredient being Meropenem Trihydrate with a content of 1g. Meropenem is a synthetic antibiotic of the carbapenem group, which has a bactericidal effect by inhibiting bacterial cell wall synthesis. The drug has a broad antibacterial spectrum against gram-negative, gram-positive, aerobic, anaerobic and beta-lactamase-producing bacteria. Gram-positive bacteria: S.pneumoniae, S.pyogenes, S. agalactiae, Staphylococcus aureus, Enterococcus faecalis (excluding Vancomycin-resistant strains). Gram-negative bacteria: Escherichia coli, Salmonella, Shigella, Haemophilus influenzae (including beta-lactamase-producing strains), Pseudomonas aeruginosa (Blue pus bacillus), Proteus mirabilis, Klebsiella pneumoniae, Neisseria meningitidis. Anaerobic bacteria: Bacteroides such as B.thetaitaomicron, B.fragilis, Peptostreptococcus.

Meropenem intravenous (IV) is indicated in cases of infections in adults and children caused by bacteria sensitive to meropenem such as:
Pneumonia, hospital-acquired pneumonia. Urinary tract infections . Abdominal infection. Gynecological infections: pelvic inflammatory disease, endometritis. Skin and soft tissue infections. Meningitis . Sepsis . Treatment is empiric with monotherapy or in combination with other antiviral or antifungal agents in cases of suspected bacterial infection in febrile neutropenic adults. Do not use Romenam in case of hypersensitivity to Meropenem or any other carbapenem antibacterial.

Dosage and duration of medication depend on the severity and type of infection as well as the patient's condition.
The recommended human dose is as follows:
Meropenem 500mg every 8 hours in cases of pneumonia, urinary tract infections, gynecological infections (endometritis), skin and soft tissue infections. Meropenem 1g every 8 hours in cases of peritonitis, hospital-acquired pneumonia, suspected bacterial infection in neutropenic patients, sepsis. Meningitis, cystic fibrosis: the recommended dose is 2g every 8 hours As with other antibiotics, caution should be taken when using meropenem as monotherapy in case of bacterial or suspected respiratory tract infection. under exacerbation caused by Pseudomonas aeruginosa. It is recommended that Meropenem sensitivity be routinely tested in the treatment of infections caused by Pseudomonas aeruginosa. Dosage should be adjusted depending on creatinine clearance in patients with renal impairment. For elderly patients with normal renal function or creatinine clearance > 50ml/min, no dose adjustment is required. No dose adjustment is required for patients with hepatic impairment. Children:
Children from 3 months to 12 years: The recommended dose is 10-20mg/kg every 8 hours. Children weighing > 50 kg: Recommended dosage as adults. Meningitis: 40mg/kg every 8 hours. There is no experience in children with impaired renal function.

When using Romenam medicine, you may experience some unwanted effects as follows:
Reactions at the injection site such as pain at the injection site, thrombophlebitis. Systemic allergic reactions such as anaphylaxis, angioedema. Skin reactions such as itching, rash, urticaria. Serious reactions such as Stevens-Johnson syndrome, erythema multiforme, toxic skin necrosis are rare. Gastrointestinal disorders: Nausea, vomiting, abdominal pain, diarrhea or pseudomembranous colitis. Thrombocytopenia, eosinophilia, leukopenia, and neutropenia are reversible. Rarely, hemolytic anemia occurs. A positive direct or indirect Coombs reaction may occur in some patients. Effects on liver function: Increase in serum transaminases, bilirubin, alkaline phosphatase, lactic dehydrogenase LDH alone or in combination. Central nervous system effects such as headache, paresthesia, convulsions Oral or vaginal candidiasis. When using Romenam medicine, if the patient experiences any serious side effects, stop taking the drug and immediately contact the treating doctor or medical facility for timely treatment.

When combined with Romenam may interact with the following drugs:
The binding of meropenem to plasma proteins is quite low (2%), so there will be essentially no interaction with other drugs due to cleavage from plasma proteins. Concomitant use of probenecid is not recommended because these two drugs compete for active tubular secretion, thereby inhibiting the excretion of meropenem, increasing the half-life and plasma concentrations of meropenem. Co-administration of meropenem with valproic acid is not recommended because it reduces the serum concentration of valproic acid and reduces the therapeutic effect.

When using Romenam, caution should be exercised in the following cases:
Cross-allergies may occur between carbapenem antibiotics other than beta-lactam antibiotics (penicillin, cephalosporins). Before initiating meropenem, a history of hypersensitivity reactions to beta-lactam antibiotics should be sought. Should be used with caution in subjects with this history of hypersensitivity. If an allergic reaction to meropenem occurs, the drug should be discontinued and immediate measures taken. When used for patients with liver damage, it is necessary to regularly monitor blood transaminase and bilirubin levels. As with other antibiotics, when taking the drug can cause the proliferation of bacteria that are not sensitive to the drug, so it is necessary to closely monitor the patient. Meropenem is not recommended for infections caused by methicillin-resistant Staphylococcus aureus. Clinically, when using the drug rarely causes pseudomembranous colitis from mild to life-threatening. Caution should be exercised when prescribing to patients with a history of gastrointestinal disease, especially colitis. In particular, the diagnosis of pseudomembranous colitis should be considered when a patient develops diarrhea associated with the use of Meropenem, and other causes should also be considered. Use with caution in combination with potentially nephrotoxic drugs. Meropenem is not recommended for use in children under 3 months of age because its efficacy and tolerability have not been established. There is no experience in children with liver or kidney dysfunction. The safety of the drug in pregnant women has not been established. Meropenem should not be used by pregnant or lactating women, unless the benefits of treatment have been carefully weighed against the possible risks to the fetus or young child. The drug does not affect the ability to drive and use machines. In addition to the above information, if you have any questions about Romenam, you can contact your doctor for advice and answers.